Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

ative Colitis - On August 24, 2010 Shire received a ruling from the US Food and Drug Administration ("FDA") on its Citizen Petition relating to PENTASA. The ruling granted Shire's request with regard to the requirement that bioequivalence to PENTASA be shown by dissolution testing and further imposed a requirement for rigorous pharmacokinetic data. The ruling denied the request that studies with clinical outcomes endpoints also be required because the FDA concluded that comparative clinical endpoint studies would be less sensitive, accurate and reproducible than pharmacokinetic studies. RESOLOR - for the treatment of chronic constipation in women - Through its acquisition of Movetis, Shire has expanded its GI presence in Europe with the recently launched RESOLOR, a new chemical entity. RESOLOR is approved in the 27 countries of the EU, Switzerland, Iceland, Lichtenstein and Norway. REPLAGAL - for the treatment of Fabry disease - REPLAGAL is now the global market leader for the treatment of Fabry disease. Shire's continuing priority is to ensure long term, uninterrupted supply at the approved dose to patients treated with REPLAGAL. There are over 2,300 patients on REPLAGAL worldwide and Shire anticipates being able to continue to accommodate additional Fabry patients in 2010 while carefully monitoring supply and demand. Shire will be in a position to make REPLAGAL available to at least 300 additional patients in 2011, phased throughout the year, based on current manufacturing capacity. Approval of the new Lexington Manufacturing facility will allow treatment of several hundred more Fabry patients with REPLAGAL, and Shire is working closely with the authorities towards this goal. VPRIV - for the treatment of Type 1 Gaucher disease - On August 26, 2010 the European Commission granted Shire marketing authorization for VPRIV, an ERT for the long-term treatment of Type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the Centralized Procedure, ma
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Fla. , Aug. 26, 2014 ... under the symbol (NUUU) has two (2) wholly- ... Our two subsidiaries harness scientifically advanced technology to ... NUUU,s Renuell Int,l, Inc. is ... anti-aging skin care products that is made possible ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
(Date:8/26/2014)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ... President and Chief Executive Officer at AMRI, will present ... September 8, 2014 at 8:45 a.m. ET. ... be accessed at AMRI,s Investor Relations web site at ... archived for 90 days following the live presentation. ...
(Date:8/26/2014)... Historically, drug development has faced a ... grow – high attrition rate, low productivity, patent ... regulatory hurdles and increasing concern about adverse ... the traditional business model of pharmaceutical companies is ... to find better ways to reduce operational costs ...
Breaking Biology Technology:Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks 2
... - Educators and software developers will have the ... learning process at the first annual Games+Learning+Society conference ... conference is being held by Games And Professional Practice ... Learning (ADL) Co-Lab and a group of instructors at ...
... Marquette University and UGS, a provider ... the largest in-kind contribution ever presented to Marquette University, in ... a market value it says is more than $30.5 million. ... Jim Factor's Geometric Modeling Lab in the Department of Mathematics, ...
... Assembly on Thursday passed AB 499, a proposed ban on ... would outlaw the cloning of embryos both for reproductive purposes ... the making of a cloned embryo for the purpose of ... were to become law would go up to ten years ...
Cached Biology Technology:Education conference to draw together games researchers 2
(Date:8/25/2014)... fires began as a lightning strike on August 12, 2014. ... 20% contained. There are close to 2,000 personnel ... many small fires and a number of large ones. ... account for about 100 acres. An inversion layer settled ... on August 24, keeping fire activity moderate. As the inversion ...
(Date:8/25/2014)... Many Americans need extraordinary willpower to avoid becoming obese ... too much. For members of minority groups, maintaining a ... new research led by Luis Rivera, an experimental social ... common for minorities in the United States to endure ... inferior, and that these attitudes can prevent people from ...
(Date:8/25/2014)... 2014 Nearly 1 in 6 adults worldwide may ... disorder can cause serious complications. Auriculotherapy, a form ... the outer ear, may help in managing constipation. ... that evaluated the effectiveness of auriculotherapy in treating ... a Review article in The Journal of ...
Breaking Biology News(10 mins):Happy Camper and July Fire Complexes in California 2Racial and ethnic stereotypes may contribute to obesity among minorities 2
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
... the value of your microarray data using ... you need from consultation to extensive data ... methods. Utilize our expertise in combination with ... your own microarray experiments., ,Normalization and basic ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... of Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving ... m/z, * Precursor ion selection range: 150 - 4000 m/z, * ... with internal reference, * Dynamic range: 4 orders of magnitude ... ...
Biology Products: